Related posters
Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice
TME composition in BRGSF-HIS mice
November 6, 2024
Background
The relevance of preclinical models has vastly improved with mice bearing a human immune system, especially in the context of immunotherapy. BRGSF (BALB/c Rag2-/-, IL2R-/-, SIRPNOD and Flt3-/-) is a highly immunodeficient mouse featuring reduced murine myeloid cells. BRGSF mice reconstituted with human cord blood CD34+ cells (BRGSF-HIS) develop functional lymphoid and myeloid compartments. This engraftment is stable over a year and mice do not develop GvHD. Additionally, myeloid compartment can be transiently boosted with exogenous human Flt3L injections. In contrary to other models which overexpress human cytokines to develop human myeloid cells, Flt3L-treated BRGSF-HIS mice do not show side effects. BRGSF-HIS mice are permissive to mouse and human cancer cell lines engraftment.
Scientific excellence
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Robust validation data on catalog models
Comprehensive dataset package
Generated with biopharma partners and in-house
Customer care
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Easy and fast access to models
Breeding facilities in US and Europe
Certified health status from professional breeders